Cargando…
P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
Autores principales: | Birndt, Sebastian, Hammersen, Jakob, Döhner, Konstanze, Reuken, Philipp, Sauerbrey, Paul, Rosée, Felicitas La, Pfirrmann, Markus, Fabisch, Christian, Illerhaus, Gerald, Weiß, Manfred, Träger, Karl, Bremer, Hinrich, Drömann, Daniel, Schneider, Sylke, Rosee, Paul La, Hochhaus, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430329/ http://dx.doi.org/10.1097/01.HS9.0000973044.21308.32 |
Ejemplares similares
-
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
por: Hammersen, J., et al.
Publicado: (2023) -
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
por: La Rosée, F., et al.
Publicado: (2020) -
The impact of specific cytokine directed treatment on severe COVID-19
por: Reuken, P. A., et al.
Publicado: (2021) -
Hemophagocytic Syndrome-Associated Intravascular Large B-cell Lymphoma With Dialysis-Dependent End-Stage Renal Disease Treated With Autologous Stem Cell Transplantation Using a Modified TEAM Regimen
por: Kama, Kudret, et al.
Publicado: (2022) -
Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation
por: La Rosée, P., et al.
Publicado: (2020)